Literature DB >> 21844929

The dark side of regulatory T cells in psoriasis.

David C Soler1, Thomas S McCormick.   

Abstract

Psoriasis is a hereditary disease elicited by chronic activation of cutaneous T cells. Delineating the mechanistic interplay of the cell subsets involved is key to developing the next generation of effective treatments. In this issue, Bovenschen et al. report that regulatory T cells maintain a fine balance between the transcription factors Foxp3 and RORγt. In patients with psoriasis, Tregs readily turn into IL-17-expressing cells, thus potentially perpetuating the inflammatory process that characterizes the disease. Results demonstrating that the histone/protein deacetylation inhibitor trichostatin A can block this conversion suggest that an epigenetic modification may underlie regulatory T-cell plasticity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844929      PMCID: PMC3366427          DOI: 10.1038/jid.2011.200

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Psoriasis and parapsoriasis: since 200 and 100 years, respectively.

Authors:  K Holubar
Journal:  J Eur Acad Dermatol Venereol       Date:  2003-03       Impact factor: 6.166

Review 2.  New insights in the immunologic basis of psoriasis.

Authors:  Kristine E Nograles; Batya Davidovici; James G Krueger
Journal:  Semin Cutan Med Surg       Date:  2010-03

3.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

4.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.

Authors:  Heon Park; Zhaoxia Li; Xuexian O Yang; Seon Hee Chang; Roza Nurieva; Yi-Hong Wang; Ying Wang; Leroy Hood; Zhou Zhu; Qiang Tian; Chen Dong
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.

Authors:  H Jorn Bovenschen; Peter C van de Kerkhof; Piet E van Erp; Rob Woestenenk; Irma Joosten; Hans J P M Koenen
Journal:  J Invest Dermatol       Date:  2011-06-09       Impact factor: 8.551

6.  IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A.

Authors:  Heather L Rizzo; Shinji Kagami; Kevin G Phillips; Stephen E Kurtz; Steven L Jacques; Andrew Blauvelt
Journal:  J Immunol       Date:  2010-12-20       Impact factor: 5.422

7.  Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Authors:  Charles A Dinarello; Gianluca Fossati; Paolo Mascagni
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

Review 8.  HDAC inhibition in lupus models.

Authors:  Christopher M Reilly; Nicole Regna; Nilamadhab Mishra
Journal:  Mol Med       Date:  2011-02-11       Impact factor: 6.354

Review 9.  Regulatory T cells and inhibitory cytokines in autoimmunity.

Authors:  Maria Bettini; Dario A A Vignali
Journal:  Curr Opin Immunol       Date:  2009-10-23       Impact factor: 7.486

10.  Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis.

Authors:  Laura E Tovar-Castillo; Juan C Cancino-Díaz; Francisco García-Vázquez; Francisco G Cancino-Gómez; Gladys León-Dorantes; Fernando Blancas-González; Luis Jiménez-Zamudio; Ethel García-Latorre; Mario E Cancino-Díaz
Journal:  Int J Dermatol       Date:  2007-03       Impact factor: 2.736

View more
  13 in total

Review 1.  Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.

Authors:  Runze Qiu; Liyu Zhou; Yuanjing Ma; Lingling Zhou; Tao Liang; Le Shi; Jun Long; Dongping Yuan
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

Review 2.  Treg functional stability and its responsiveness to the microenvironment.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

3.  Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

Authors:  Xuehui He; Hans J P M Koenen; Ruben L Smeets; Romy Keijsers; Esther van Rijssen; Andreas Koerber; Peter C van de Kerkhof; Annemieke M H Boots; Irma Joosten
Journal:  J Invest Dermatol       Date:  2013-11-05       Impact factor: 8.551

Review 4.  Current and potential immune therapies and vaccines in the management of psoriasis.

Authors:  Benjamin H Kaffenberger; Grace L Lee; Kelly Tyler; Derek V Chan; Wael Jarjour; Maria E Ariza; Marshall V Williams; Henry K Wong
Journal:  Hum Vaccin Immunother       Date:  2014-02-03       Impact factor: 3.452

5.  Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity.

Authors:  Priscilla Stela Santana de Oliveira; Michelly Cristiny Pereira; Simão Kalebe Silva de Paula; Emerson Vasconcelos Andrade Lima; Mariana Modesto de Andrade Lima; Rodrigo Gomes de Arruda; Wagner Luís Mendes de Oliveira; Ângela Luzia Branco Pinto Duarte; Ivan da Rocha Pitta; Moacyr Jesus Melo Barreto Rêgo; Maira Galdino da Rocha Pitta
Journal:  Mediators Inflamm       Date:  2016-11-30       Impact factor: 4.711

6.  Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy.

Authors:  Chao Chen; Lirong Tan; Wu Zhu; Li Lei; Yehong Kuang; Panpan Liu; Jie Li; Xiang Chen; Cong Peng
Journal:  Mediators Inflamm       Date:  2020-06-28       Impact factor: 4.711

7.  Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8+ T cell response.

Authors:  Krista Stockenhuber; Ahmed N Hegazy; Nathaniel R West; Nicholas E Ilott; Alexander Stockenhuber; Samuel J Bullers; Emily E Thornton; Isabelle C Arnold; Andrea Tucci; Herman Waldmann; Graham S Ogg; Fiona Powrie
Journal:  J Exp Med       Date:  2018-07-06       Impact factor: 14.307

8.  Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients.

Authors:  Sandro C Furiati; Jonatas S Catarino; Marcos V Silva; Rafaela F Silva; Rayane B Estevam; Reginaldo B Teodoro; Sanivia L Pereira; Meire Ataide; Virmondes Rodrigues; Denise B R Rodrigues
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

9.  Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach.

Authors:  Máté Manczinger; Lajos Kemény
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

10.  Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.

Authors:  Agnes Szentpetery; Eric Heffernan; Martina Gogarty; Lisa Mellerick; Janet McCormack; Muhammad Haroon; Musaab Elmamoun; Phil Gallagher; Genevieve Kelly; Aurelie Fabre; Brian Kirby; Oliver FitzGerald
Journal:  Arthritis Res Ther       Date:  2017-07-05       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.